New-onset gout after kidney transplantation: Incidence, risk factors and implications

Transplantation

Volumn 80, Issue 10, 2005, Pages 1383-1391

  Abbott, Kevin C ^a,b   Kimmel, Paul L ^c   Dharnidharka, Vikas ^d   Oglesby, Robert J ^a,b   Agodoa, Lawrence Y ^e   Caillard, Sophie ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Age; Body mass index; Creatinine; Cyclosporine; End stage kidney disease; Glomerular filtration rate; Kidney transplant; Medicare claim; New onset gout; Obesity; USRDS

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

AGE DISTRIBUTION; ARTICLE; BODY MASS; CONFIDENCE INTERVAL; FEMALE; GOUT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MEDICARE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

BODY MASS INDEX; CYCLOSPORINE; FEMALE; GOUT; HUMANS; HYPERURICEMIA; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTORS; TACROLIMUS; UNITED STATES;

EID: 29144531158     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000188722.84775.af     Document Type: Article

References (43)

1. Clive DM. Renal transplant-associated hyperuricemia and new-onset gout. J Am Soc Nephrol 2000 May; 11 (5): 974-9.
2. Baroletti S, Bencivenga GA, Gabardi S. Treating new-onset gout in kidney transplant recipients. Prog Transplant 2004 Jun; 14 (2): 143-7.
3. Marcen R, Gallego N, Orofino L, Sabater J, Pascual J, Teruel JL, Liano F, Ortuno J. Influence of cyclosporin A (CyA) on renal handling of urate. Transpl Int. 1992; 5 Suppl 1: S81-3.
4. Abdelrahman M, Rafi A, Ghacha R, Youmbissi JT, Qayyum T, Karkar A. Hyperuricemia and new-onset gout in renal transplant recipients. Ren Fail 2002 May; 24 (3): 361-7.
5. Pilmore HL, Faire B, Dittmer I. Tacrolimus for the treatment of new-onset gout in renal transplantation: two case reports and review of the literature. Transplantation 2001 Nov 27; 72 (10): 1703-5.
6. Venkat Raman G, Sharman VL, Lee HA. Azathioprine and allopurinol: a potentially dangerous combination. J Intern Med 1990 Jul; 228 (1): 69-71.
7. Niskanen LK, Laaksonen DE, Nyyssonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004 Jul 26; 164 (14): 1546-51.
8. Iseki K, Ikemiya Y, Inoue T, Iseki C, Kinjo K, Takishita S. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004 Oct; 44 (4): 642-50.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 Mar 16; 130 (6): 461-70.
10. Pascual E, Pedraz T. New-onset gout. Curr Opin Rheumatol 2004; 16: 282-6.
11. Hosmer DW, Lemeshow S. Applied Survival Analysis, Chapter 5, Model Development, page 158. John Wiley and Sons Inc, 1999, New York.
12. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, Woodworth TG, Brennan DC. Incidence and cost of new-onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3 (5): 590-8.
13. Ifudu O, Tan CC, Dulin AL, Delano BG, Friedman EA. Gouty arthritis in end-stage renal disease: clinical course and rarity of new cases. Am J Kidney Dis 1994; 23 (3): 347-51.
14. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Kidney Int 1998 Sep; 54 (3): 938-44.
15. Mazzali M, Kim YG, Suga S, Gordon KL, Kang DH, Jefferson JA, Hughes J, Kivlighn SD, Lan HY, Johnson RJ. Hyperuricemia exacerbates chronic cyclosporine nephropathy. Transplantation 2001 Apr 15; 71 (7): 900-5.
16. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and new-onset gout. N Engl J Med 1989; 321: 287-92.
17. Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 2001; 14: 370-83.
18. Shibolet O, Elinav E, Ilan Y, Safadi R, Ashur Y, Eid A, Zamir G, Fridlander M, Bdolah-Abram T, Shouval D, Admon D. Reduced incidence of hyperuricemia, new-onset gout, and renal failure following liver transplantation in comparison to heart transplantation: a long-term follow-up study. Transplantation 2004; 77: 1576-80.
19. Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant 2003 Oct; 18 (10): 2147-53.
20. Zawadzki J, Grenda R, Januszewicz P. Effect of nifedipine on tubular handling of uric acid in transplanted kidney on cyclosporine A treatment. Nephron 1995; 70 (1): 77-82.
21. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of new-onset gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004 Aug; 31 (8): 1582-7.
22. Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HR Jr., Saag KG. New-onset gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann Rheum Dis 2005 Feb; 64 (2): 267-72.
23. Kim KY, Ralph Schumacher H, Hunsche E, Wertheimer AI, Kong SX. A literature review of the epidemiology and treatment of acute new-onset gout. Clin Ther 2003 Jun; 25 (6): 1593-617.
24. Janssens HJ, van de Lisdonk EH, Bor H, van den Hoogen HJ, Janssen M. New-onset gout, just a nasty event or a cardiovascular signal? A study from primary care. Fam Pract 2003 Aug; 20 (4): 413-6.
25. Lyu LC, Hsu CY, Yeh CY, Lee MS, Huang SH, Chen CL. A case-control study of the association of diet and obesity with new-onset gout in Taiwan. Am H Clin Nutr 2003 Oct; 78 (4): 690-701.
26. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003 Mar; 63 (3): 793-808.
27. Ruilope LM, Garcia-Puig J. Hyperuricemia and renal function. Curr Hypertens Rep 2001 Jun; 3 (3): 197-202.
28. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, Garcia-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic new-onset gout after proper control of hyperuricemia and new-onset gouty bouts. Nephron 2000 Nov; 86 (3): 287-91.
29. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. Am J Kidney Dis 1999 Feb; 33 (2): 225-34.
30. Jee SH, Lee SY, Kim MT. Serum uric acid and risk of death from cancer, cardiovascular disease or all causes in men. Eur J Cardiovasc Prev Rehabil 2004 Jun; 11 (3): 185-91.
31. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003 Apr 22; 107 (15): 1991-7.
32. Doehner W, Anker SD. Uric acid in chronic heart failure. Semin Nephrol 2005 Jan; 25 (1): 61-66.
33. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991 May 5; 266 (13): 8604-8.
34. Mazzali M. Uric acid and transplantation. Semin Nephrol 2005 Jan; 25 (1): 50-55.
35. Kang DH, Nakagawa T. Uric acid and chronic renal disease: Possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005 Jan; 25 (1): 43-49.
36. Perico N, Codreanu I, Caruso M, Remuzzi G. Contrib Nephrol 2005; 147: 124-31.
37. Kang DH, Nakagawa T. Uric acid and chronic renal disease: Possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005 Jan; 25 (1): 43-9.
38. Netea MG, Kullberg BJ, Blok WL, Netea RT, van der Meer JW. The role of hyperuricemia in the increased cytokine production after lpopolysaccharide challenge in neutropenic mice. Blood 1997 Jan 15; 89 (2): 577-82.
39. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003 Oct 2; 425 (6957): 516-21.
40. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, Nepomuceno T, Rodriguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005 Jan; 67 (1): 237-47.
41. Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA 2000 Feb 2; 283 (5): 633-8.
42. Short RA, Tuttle KR. Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: A statistical modeling perspective. Semin Nephrol 2005 Jan; 25 (1): 25-31.
43. Baroletti S, Bencivenga GA, Gabardi S. Treating new-onset gout in kidney transplant recipients. Prog Transplant 2004 Jun; 14 (2): 143-7.